Hf Arzneimittelforschung Gmbh

Arzneimittelforschung Gmbh & Co. Kg

Therapie-system Gmbh & Co., Kg

Janssen Pharmaceutica Nv

Joachim Moormann

Thomas Hille

Hans-Rainer Hoffmann

Rudolf Matusch

Bodo Asmussen

Frank Becher

Klaus Opitz

Hermann Mucke

The invention relates to the use of galanthamine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.

Use of galanthamine for the treatment of pathological manifestations of the central nervous system based on intoxications with psychotropic substances

Processes for the production of a compound of the following formula (I) by converting a compound of formula (II) with 2-pyrrolidone used in excess relative to compound (II) and processes for the production of a compound of formula (III). The latter process includes preparing compound (I); a reduction reaction which yields compound (III) in salt form; and liberating compound (III) from the salt.

Processes for the production of chinazoline alkaloids

Pharmaceutical formulation for the treatment of nicotine dependence

Growing community of inventors

Werne, Germany

Joachim Moormann